Tranexamic Acid Side Effects: Rare but Serious Adverse Events Every Woman Should Know

Why Rare Adverse Events Deserve a Dedicated Conversation

Most women tolerate tranexamic acid without incident. The key phase 3 trial supporting the Lysteda oral formulation, published in the American Journal of Obstetrics and Gynecology, reported that nausea, headache, and musculoskeletal pain were the dominant complaints, affecting roughly 20 percent of participants. But "rare" does not mean "impossible," and for a drug that 1 in 5 women of reproductive age could theoretically use at some point for heavy menstrual bleeding, even a 0.5 percent incidence of a serious event translates to thousands of women annually.

Rare serious adverse events in pharmacology are typically defined as those occurring in fewer than 1 in 1,000 users. For tranexamic acid, these cluster into four categories: thromboembolic events, hypersensitivity and anaphylaxis, seizures, and visual or retinal disturbances. Each has a distinct mechanism, a distinct risk population, and a distinct clinical signal a woman should know to watch for.

The Evidence Gap Women Deserve to Hear About

Clinical trial populations for tranexamic acid have skewed toward younger reproductive-age women, which means data for perimenopausal women, women with metabolic comorbidities, and postmenopausal women using it for other indications (such as topical skin formulations or off-label endometriotic bleeding) are thin. Women were also under-represented in many surgical trials of high-dose IV tranexamic acid where seizure data originate. Where evidence is extrapolated from male or mixed-sex surgical populations, this article says so explicitly.

Thromboembolic Events: The Risk That Matters Most for Women

The mechanism of tranexamic acid is antifibrinolytic: it blocks lysine-binding sites on plasminogen, preventing fibrin clot dissolution. That same mechanism, in theory, could tip the balance toward excessive clotting. The practical question is whether oral tranexamic acid at standard HMB doses meaningfully raises thrombosis risk in otherwise healthy women.

What the Trial Data Actually Show

The Lysteda phase 3 program did not observe a statistically elevated rate of venous thromboembolism compared with placebo. The prescribing information for Lysteda notes that VTE has been reported in post-marketing surveillance but does not list a confirmed incidence rate, because causality in post-market reports is difficult to establish.

The CRASH-2 trial, which randomized more than 20,000 trauma patients to IV tranexamic acid or placebo, found no significant increase in fatal or non-fatal VTE in the treatment arm. However, CRASH-2 was a surgical and trauma population receiving a one-time or short-course dose, not repeated five-day monthly cycles as used for HMB. Direct extrapolation has limits.

A 2021 systematic review in Thrombosis Research examined thromboembolic events in women using oral tranexamic acid for HMB and concluded that absolute VTE risk appeared low, estimated at approximately 0 to 1 additional event per 10,000 women treated, though the authors flagged that most studies excluded women at high baseline thrombotic risk.

Combined Oral Contraceptive Use: The Combination to Watch

This is where the risk picture changes. COCs independently raise VTE risk by approximately three- to fourfold over baseline, depending on the progestin type and estrogen dose. Tranexamic acid's antifibrinolytic action layered onto that hormonal shift has not been studied in a powered randomized trial. The Lysteda label carries a specific note that the drug has not been studied in women taking hormonal contraceptives and that concomitant use "may increase the risk of thromboembolic adverse reactions." ACOG's 2013 and updated guidance on HMB management acknowledges this gap and recommends individual clinical assessment before combining the two treatments.

Who Carries the Highest Thrombotic Risk

Women with any of the following should have an explicit discussion with their clinician before starting tranexamic acid:

• Personal or family history of DVT, pulmonary embolism, or stroke
• Known thrombophilia (Factor V Leiden, prothrombin gene mutation, antiphospholipid antibody syndrome)
• Active COC or patch or ring use
• Immobility or recent surgery
• Active malignancy
• BMI >35 combined with additional risk factors

Postmenopausal women prescribed tranexamic acid off-label for bleeding complications of hormone therapy also carry an older-age baseline thrombotic risk that is not captured in HMB trial populations.

Seizures: High-Dose Risk, Not Standard HMB Risk

Seizures are among the most alarming entries in tranexamic acid's adverse-event profile, but context matters enormously here.

Where the Seizure Data Come From

Nearly all seizure reports originate from high-dose intravenous tranexamic acid in cardiac surgery, where doses of 50 to 150 mg/kg are used, levels orders of magnitude above the 1,300 mg oral three-times-daily HMB dose. A 2012 meta-analysis in Anesthesia and Analgesia found a pooled seizure incidence of approximately 7.6 percent in cardiac surgery patients receiving high-dose IV tranexamic acid versus under 1 percent with lower-dose regimens. The proposed mechanism is glycine-receptor antagonism in the central nervous system at high CSF concentrations, an effect that does not appear to occur at oral HMB doses.

No published case series documents seizures in women taking oral tranexamic acid at the FDA-approved 1,300 mg three-times-daily schedule. The FAERS database (FDA Adverse Event Reporting System) does contain seizure entries for tranexamic acid, but the majority do not specify route, dose, or indication, making women-specific attribution impossible.

What This Means for You

If you are taking oral Lysteda or a generic equivalent for heavy periods, the seizure warning on the label reflects the drug class at high doses, not a documented risk at your prescribed dose. Women with a personal history of epilepsy or who take other medications that lower seizure threshold should still flag this to their prescriber, because individual pharmacokinetics vary and drug interactions could theoretically raise CNS exposure.

Hypersensitivity and Anaphylaxis

Severe allergic reactions to tranexamic acid are rare but documented. The mechanism is likely IgE-mediated or complement-driven, and reports include urticaria, angioedema, bronchospasm, and full anaphylaxis. Post-marketing case reports collated in the European Medicines Agency database and in FAERS describe anaphylaxis most commonly with IV administration, though oral-route cases exist.

Women with known hypersensitivity to tranexamic acid should not receive the drug in any form. Cross-reactivity with other antifibrinolytics (aminocaproic acid, aprotinin) is theoretically possible but not systematically studied.

Signs to seek emergency care for immediately after any dose:

• Throat tightening, difficulty swallowing, or swallowing
• Hives that spread rapidly
• Sudden drop in blood pressure or loss of consciousness
• Wheezing or severe shortness of breath

Visual Disturbances and Retinal Vascular Events

Tranexamic acid's labeling includes a warning about visual disturbances, based primarily on animal toxicity data showing retinal degeneration at very high doses and on a small number of post-market reports in humans. The Lysteda prescribing information recommends discontinuing the drug if any visual changes occur and referring promptly to ophthalmology.

Retinal vein or artery occlusion has been reported rarely and may share a pathophysiologic pathway with the drug's antifibrinolytic mechanism in the retinal microvasculature. These events are more common with IV administration in high-risk surgical patients. For women using the oral form for HMB, the absolute risk is very low, but any sudden change in vision, floaters, visual field loss, or color disturbance during treatment is a reason to stop the drug and seek same-day evaluation.

Renal Impairment: Why Dose Adjustment Matters

Tranexamic acid is renally cleared. In women with chronic kidney disease stages 3 through 5, drug accumulation increases significantly, raising both antifibrinolytic effect and CNS exposure. The prescribing information specifies dose reductions based on serum creatinine:

• Creatinine 1.4 to 2.8 mg/dL: 1,300 mg twice daily
• Creatinine 2.9 to 5.7 mg/dL: 1,300 mg once daily
• Creatinine >5.7 mg/dL: 650 mg once daily

Women with PCOS who have developed insulin-resistant nephropathy, women with lupus nephritis, and women with longstanding hypertension should have their kidney function assessed before starting tranexamic acid. This is a group that women's health providers often see but that HMB trials largely excluded.

Pregnancy and Lactation Safety

Tranexamic acid does not have FDA pregnancy letter categories under the current labeling system, but the available human data can be parsed by trimester and indication.

First Trimester and Organogenesis

Animal reproductive studies at doses several times the human equivalent did not show clear teratogenicity. Human data are largely observational. A Danish register-based cohort study of more than 1,600 women exposed to tranexamic acid during pregnancy found no statistically significant increase in major congenital malformations compared with unexposed controls. This study is reassuring but cannot rule out small risk increases for rare defects because of sample size.

Tranexamic acid does cross the placenta. Placental transfer studies show fetal plasma concentrations approximately equal to maternal concentrations, meaning the fetus is exposed to full drug levels. The clinical implication is that the drug's antifibrinolytic effect is active in fetal circulation, which is why routine use in the first trimester for non-urgent indications is not recommended.

Obstetric Use: Postpartum Hemorrhage

The most evidence-rich use of tranexamic acid in pregnancy is for postpartum hemorrhage (PPH). The WOMAN trial, published in The Lancet in 2017, randomized 20,060 women with PPH to IV tranexamic acid or placebo within three hours of birth. Tranexamic acid reduced death from bleeding by 19 percent (relative risk 0.81, 95% CI 0.65 to 1.00) with no increase in thromboembolic complications in the treated group. ACOG Practice Bulletin 183 on Postpartum Hemorrhage endorses tranexamic acid as an adjunct treatment for PPH when oxytocin and uterotonic agents are insufficient.

This means a clinician administering tranexamic acid IV during a life-threatening postpartum bleed is acting on strong trial evidence. That is a different clinical context from elective oral use for menstrual bleeding during pregnancy.

Lactation

Tranexamic acid transfers into breast milk. Published pharmacokinetic data from the Swedish Adverse Drug Reactions Advisory Committee show milk-to-plasma ratios suggesting infant exposure of less than 1 percent of the maternal weight-adjusted dose. LactMed, the NIH lactation database, classifies tranexamic acid as likely compatible with breastfeeding at standard doses, noting that the oral bioavailability of the drug in infants is uncertain but that the absolute amount ingested is small.

Postpartum women in the fourth trimester who need treatment for abnormal uterine bleeding should discuss the lactation profile with their provider. The current evidence does not require pumping-and-discarding at standard HMB doses, but this decision should be individualized.

Contraception Requirement

Tranexamic acid is not classified as a teratogen requiring mandatory contraception, unlike drugs such as isotretinoin or valproate. Women of reproductive age who could become pregnant should be counseled that first-trimester safety data are limited and that, if pregnancy is planned, a conversation about whether continued use of tranexamic acid is appropriate should happen before conception, not after a positive test.

Who This Drug Is and Is Not Right For, by Life Stage

Reproductive Years (Ages 18 to 40)

This is the primary approved population. Women with no thrombophilia, no active hormonal contraceptive use, and no renal impairment have the most favorable benefit-risk profile. Tranexamic acid reduces mean menstrual blood loss by approximately 40 percent compared with placebo in women with HMB, making it one of the most effective non-hormonal options available.

Women with PCOS and anovulatory heavy bleeding may use tranexamic acid for episodic cycle management. Insulin resistance in PCOS does not directly contraindicate the drug, but clinicians should assess whether the anovulatory state itself increases thrombotic baseline risk.

Women with von Willebrand disease type 1 have specific evidence supporting tranexamic acid use. ACOG Committee Opinion 580 identifies it as a first-line hemostatic option in this population.

Trying to Conceive

Tranexamic acid should be used only during the menstrual phase (days 1 through 5) in women actively trying to conceive. Use during the luteal phase, when implantation occurs, is not recommended because of theoretical effects on fibrinolysis at the implantation site. No trial has directly studied TTC-phase safety.

Perimenopause

Perimenopausal women with erratic, heavy bleeding represent a clinically important group that is under-studied in tranexamic acid trials. In this life stage, the estrogen-dominant anovulatory cycles can produce substantial endometrial buildup and flooding episodes. Tranexamic acid offers episodic hemostatic control without hormonal content, which is attractive when hormonal treatment is contraindicated or declined.

The caveat: perimenopausal women have a higher baseline cardiovascular risk than younger women. The absolute VTE risk from tranexamic acid, even if small, lands on a higher-risk baseline. Any perimenopausal woman with additional cardiovascular risk factors (hypertension, smoking, obesity, personal history of VTE) should have a frank individual discussion before starting treatment.

Postmenopause

Postmenopausal women are not a labeled population for oral tranexamic acid. If postmenopausal bleeding is present, the clinical priority is ruling out endometrial pathology, not treating the bleeding symptomatically. Using tranexamic acid to manage postmenopausal bleeding without completing this workup is not appropriate.

Drug Interactions That Raise Adverse Event Risk

Tranexamic acid has relatively few pharmacokinetic drug interactions, but pharmacodynamic interactions matter clinically:

• Combined oral contraceptives and hormonal patches/rings: additive prothrombotic risk (discussed above)
• Factor IX complex concentrates and anti-inhibitor coagulant concentrates: concomitant use is contraindicated in the prescribing information because of reports of thrombosis
• All-trans retinoic acid (ATRA): case reports of fatal thrombosis in patients with acute promyelocytic leukemia receiving both agents; avoid combination
• Hormonal replacement therapy: theoretical additive prothrombotic effect in perimenopausal or postmenopausal women; clinical data are absent

Recognizing a Serious Adverse Event: A Practical Guide

The following framework is designed to help you distinguish common side effects (nausea, headache) from warning signs that require immediate medical contact.

| Symptom | What It Might Signal | Action | |---|---|---| | Leg pain, swelling, warmth in one calf | Deep vein thrombosis | Stop drug, go to emergency department | | Sudden chest pain or breathlessness | Pulmonary embolism | Call 911 immediately | | Sudden severe headache, face drooping, arm weakness | Stroke | Call 911 immediately | | Sudden vision loss or floaters | Retinal vascular event | Stop drug, same-day ophthalmology | | Throat tightening, hives, wheezing | Anaphylaxis | Call 911 immediately | | Seizure or uncontrolled shaking | CNS toxicity (rare at oral doses) | Call 911 immediately |

FAERS Signal Data and Post-Market Surveillance

The FDA Adverse Event Reporting System is an imperfect but informative signal source. As of the most recent publicly available quarterly data, tranexamic acid FAERS entries include thromboembolic events, hypersensitivity reactions, and visual disturbances, though under-reporting and confounding by indication mean incidence cannot be calculated from FAERS alone. The FDA's MedWatch program provides a mechanism for clinicians and patients to report new or unexpected adverse events, and women who experience a serious event on tranexamic acid are encouraged to report through this channel.

Post-market surveillance in European registries has not identified a new safety signal beyond those in the original label, according to the European Medicines Agency's product assessment reports. This is modestly reassuring, but the duration of formal surveillance for the oral HMB indication remains shorter than for drugs approved decades ago.

Monitoring While on Tranexamic Acid

For most women using oral tranexamic acid for HMB, no routine laboratory monitoring is required during treatment. The following situations warrant a baseline or ongoing assessment:

• Renal function (serum creatinine) if you have diabetes, hypertension, lupus, or a history of kidney disease
• Thrombophilia screening if you have a personal or strong family history of VTE, before the first prescription is written
• Ophthalmologic baseline if you have a history of retinal disease or are using the drug long-term (beyond 12 months continuous use is not typical for HMB but occurs in some women with refractory bleeding)

The prescribing information does not mandate routine monitoring for women with no risk factors, and this is consistent with current clinical practice. If your symptoms change or new symptoms appear, re-evaluation is always appropriate.